Código QR (código de barras bidimensional)

Immunogenicity and safety of the first indigenously developed Indian tetravalent influenza vaccine (split virion) in healthy adults ≥ 18 years of age: A randomized, multicenter, phase II / III clinical trial

This phase II / III clinical trial was conducted to evaluate the immunogenicity and safety of the Tetravalent Influenza vaccine (Split virion) I.P. (TetIV) developed indigenously in the country for the first time by M/s Cadila Healthcare Limited, India containing two influenza A and two influenza B...

Fuld beskrivelse

Na minha lista:
Principais autores: Shrikant Sharma, Veer Bahadur Singh, Sanjay Kumar, Vipul Prajapati, Jitendra Patel, Rajesh Vukkala, Sanjay Kumar Jangid, Jayesh Sanmukhani, Gaurav Gupta, Pradip Patel, Ravindra Mittal, Reinhard Glueck
Format: Artigo
Sprog:Inglês
Udgivet: Taylor & Francis Group 2018-06-01
Serier:Human Vaccines & Immunotherapeutics
Fag:
tetravalent influenza vaccine
trivalent influenza vaccine
immunogenicity
cadila healthcare limited
vaxigrip
sanofi pasteur
Online adgang:http://dx.doi.org/10.1080/21645515.2018.1441654
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker